Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes
L. Kristin Newby, MD, MHS, FACC*,*,
Matthew T. Roe, MD, MHS, FACC*,
Anita Y. Chen, MS*,
E. Magnus Ohman, MD, FACC ,
Robert H. Christenson, PhD ,
Charles V. Pollack, Jr, MD, MA ,
James W. Hoekstra, MD||,
W. Frank Peacock, MD¶,
Robert A. Harrington, MD, FACC*,
Robert L. Jesse, MD, PhD, FACC**,
W. Brian Gibler, MD,
Eric D. Peterson, MD, MPH, FACC* for the CRUSADE Investigators
* Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Division of Cardiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina
Department of Pathology, University of Maryland, Baltimore, Maryland
Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania
|| Department of Emergency Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina
¶ Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
** Division of Cardiology, Medical College of Virginia and Veterans Administration Medical Center, Richmond, Virginia
Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
View larger version (10K):
[in a new window]
|
Figure 1 Odds ratios with 95% confidence intervals for acute use of glycoprotein (GP) IIb/IIIa inhibitors, clopidogrel, and an early invasive management strategy. CK-MB = creatine kinase-MB; cTn = cardiac troponin.
|
|
|
